MedPath

Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation

Not Applicable
Completed
Conditions
Dry Eye Syndromes
Interventions
Device: Oculeve Intranasal Lacrimal Neurostimulator
Registration Number
NCT02385292
Lead Sponsor
Oculeve, Inc.
Brief Summary

The objectives of this study are:

* To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications

* To compare the goblet cell count following application between the intranasal and extranasal applications

* To compare fluorescein tear clearance with the application of the device intranasally and extranasally applications

Detailed Description

In this study, subjects will participate for three study days during up to a 44 day period, consisting of a screening examination to determine eligibility on one day and study applications on two different days. There are two applications, intranasal and extranasal. Subjects will receive both applications, in random sequence, one at each of the two application days (Visit 2 and Visit 3). The two applications consist of:

* Active intranasal device application

* Active extranasal device application

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
23
Inclusion Criteria
  • Bilateral dry eyes
  • Capable of providing written informed consent
Exclusion Criteria
  • Chronic or recurring epistaxis (nosebleeds)
  • Blood coagulation disorder
  • Uncontrolled or poorly controlled diabetes
  • Heart or pulmonary disease
  • Females who are pregnant, planning a pregnancy or nursing

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Intranasal then Extranasal ApplicationOculeve Intranasal Lacrimal NeurostimulatorIntranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
Extranasal then Intranasal ApplicationOculeve Intranasal Lacrimal NeurostimulatorExtranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
Primary Outcome Measures
NameTimeMethod
Fluorescein Tear Clearance With ApplicationDay 1
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Grutzmacher, Lewis & Sierra

🇺🇸

Sacramento, California, United States

Baylor College of Medicine, Department of Ophthalmology

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath